Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of October 2024, specifically dated October 3, 2024. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS).
Key Financial Metrics
The filing details a specific capital transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow.
- Share Repurchase Price: Aggregate purchase price of £230 million.
- Shares Repurchased: 60,526,315 ordinary shares purchased from Pfizer Inc.
- Shares Cancelled: 30,161,278 shares.
- Treasury Shares: 30,365,037 shares held as treasury stock.
- Total Issued Shares: 9,083,725,919 as of October 3, 2024.
- Voting Shares: 9,053,360,882 ordinary shares with voting rights.
The filing text does not provide clear values for revenue, profit, margins, debt, or liquidity positions.
Material Changes
The primary material change reported is the completion of an off-market share purchase from Pfizer Inc. This transaction has reduced the number of shares outstanding and established a specific count of treasury shares, altering the denominator for shareholder notification calculations under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosure of the share repurchase mechanics. No unusual items or contingencies were reported in this specific announcement.
Investor Verification Checklist
- Verify the updated share count of 9,053,360,882 voting shares for compliance with disclosure thresholds.
- Confirm the allocation of the £230 million expenditure between cancelled shares and treasury shares.
- Review subsequent filings for the impact of this capital return on future earnings per share (EPS) calculations.
- Check the company's latest 20-F or interim reports for comprehensive financial metrics not included in this 6-K.